Research and development daily GNI Group F351 treatment of hepatitis B-related liver fibrosis In China Phase II research success.

2020.08.18 Research and Development NEWS: Tianmai biorecombinant human insulin intestinal capsule (ORMD-0801) started Phase III clinical; We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference.
(click on the title, read the original article) "Drug Research and Development" GNI Group F351 (hydroxycodone) treatment of hepatitis B-related hepatic fibrosis China Phase II research success Japan GNI Group recently announced that the evaluation of F351 (hydroxycodone) treatment of hepatitis B-related liver fibrosis in China Phase II clinical study in the main endpoint analysis obtained positive results.
was a randomized, double-blind, placebo-controlled, multi-center, dose-incremental study that evaluated the efficacy and safety of F351 in treating liver fibrosis in patients with chronic hepatitis B in China.
pioneering the pharmaceutical industry "Frantany" to start Phase II clinical 17, to open up the pharmaceutical industry 1 new drug, Frietha Ennin to start Phase II clinical, the drug is its own research and development of an AR antagonist, used in the treatment of adult male male androgen baldness in China.
Tianmai biocombinant human insulin intestinal capsule (ORMD-0801) started Phase III clinical recently, Insight database shows that Hefei Tianmai Bio and Israel Oramed Co., Ltd. jointly developed a new oral insulin drug ORMD-0801 in China to start Phase III clinical, oral insulin is a big step closer to the market.
Drug Approval: Assisted treatment of small cell lung cancer G1 CDK4/6 inhibitors received FDA priority review on the 17th, G1 Therapeutics announced that the FDA has accepted its Trilaciclib as a new application for bone marrow protection therapy for patients with small cell lung cancer treated with chemotherapy, and given priority review, with the target date for prescription drug user fees being February 15, 2021.
Myovant oral GnRH inhibitor relugolix compound tablets entered the U.S. for review, Myovant Sciences announced that the FDA has accepted applications for new drugs for relugolix compound tablets (40mg, 1.0mg of estradiol, 0.5mg of acetic acid phenosterone), which is used once a day or so for women to treat moderate-heavy symptoms associated with uterine fibroids.
Conning Jerry PD-L1/CTLA-4 dual-anti-re-approved clinical CDE latest publicity, Corning Jerry's recombinant humanized PD-L1/CTLA-4 dual-specific monomediogenic antibody Fc fusion protein injection obtained a clinical trial implied license to develop an adaptation of: toluene sulfonate polynabinated tablets for the treatment of advanced digestive tract solid tumors.
Nine-Year Pharmaceutical Acautamine Tablets were approved for drug clinical trials notice 18, Hunan Nine-Year Pharmaceuticals announced that the company recently received the State Drug Administration issued the "Drug Clinical Trial Approval Notice", after the completion of the relevant preparations will be carried out clinical trial research.
Beijing Shuanglue Pharmaceutical Liraglutide Injection approved clinical Beijing Shuanglue Pharmaceuticals issued a notice on the 18th, the company recently received the State Drug Administration issued on liraglutide injection "Drug Clinical Trial Approval Notice."
Jiangsu Jiayi Pharmaceutical "Apixaban tablets" evaluation 18, the State Drug Administration official website shows that Jiangsu Jiayi Pharmaceuticals "Apixaban tablets" was approved, according to the new registration classification 4 categories were approved as passing a consistent evaluation.
Research and Development Cooperation Gilead and Tango ExpandEd Oncology Strategy Cooperation 17, Gilead and Tango Therapeutics announced the expansion of strategic cooperation to identify, develop and commercialize innovative immunology-specific therapies for cancer patients, with a portfolio value of up to $6 billion.
.